Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937675 · ClinicalTrials.gov registry record · Phase 1
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
A Phase 1 study, sponsored by Effector Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02937675 is a Phase 1 study that was terminated before completion, run by Effector Therapeutics. The registered enrollment target is 28 participants.
The verdict
NCT02937675, a Phase 1 study, was terminated before completion, sponsored by Effector Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508). The study will evaluate oral daily administration of Tomivosertib (eFT-508). Treatment and study subject evaluation will be performed in 21-day cycles.
Interventions
- DRUG Tomivosertib (eFT-508)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-02-08 |
| Est. Completion | 2019-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02937675
The ClinicalTrials.gov registry entry for NCT02937675 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Effector Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tomivosertib (eFT-508) is the first listed.
NCT02937675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02937675 about?
NCT02937675 is a clinical study titled "A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies". This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508). The study will evaluate oral daily administration of Tomivosertib (eFT-508). Treat...
What is the current status of trial NCT02937675?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2017-02-08. Estimated completion is 2019-04-04.
What interventions are being tested in trial NCT02937675?
The interventions under investigation include: Tomivosertib (eFT-508) (DRUG).
Who is sponsoring clinical trial NCT02937675?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.